

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Raptor Pharmaceutical Corp  
Form 8-K  
February 25, 2016

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 25, 2016

---

RAPTOR PHARMACEUTICAL CORP.  
(Exact name of registrant as specified in its charter)

---

Delaware	000-25571	86-0883978
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

7 Hamilton Landing, Suite 100  
Novato, California 94949  
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (415) 408-6200

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---



## Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

### Item 2.02 Results of Operations and Financial Condition.

On February 25, 2016, Raptor Pharmaceutical Corp. (the "Company"), issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2015. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

### Item 9.01 Financial Statements and Exhibits.

#### (d) Exhibits.

#### Exhibit

No.	Exhibit Description
99.1	Press Release issued by Raptor Pharmaceutical Corp. dated February 25, 2016.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 25, 2016 RAPTOR  
PHARMACEUTICAL CORP.

By: /s/ Michael P. Smith  
Name: Michael P. Smith  
Title: Chief Financial Officer

---

Exhibit Index

Exhibit No. Exhibit Description

99.1 Press Release issued by Raptor Pharmaceutical Corp. dated February 25, 2016.

---